Although numerous studies have examined bacterial and mycobacterial resistance in the tropics, less is known about the susceptibility profiles of medically important fungi to antifungal agents
NOXAFIL is currently awaiting approval in the European Union (EU) for use in treating certain serious invasive fungal infections in adult patients with disease that is refractory to or who are intolerant of certain commonly used antifungal agents
MYCAMINE is a member of a newer class of antifungal agents
, the echinocandins.
March 3 /PRNewswire/ -- Anacor Pharmaceuticals, a private pharmaceutical company developing novel agents for inflammatory and infectious diseases, today presented positive preclinical results for AN2690, the first in a new class of antifungal agents
in development as a topical treatment for onychomycosis, a fungal infection of the toenail and fingernails.
27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that the European Commission has granted marketing approval to NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of certain serious invasive fungal infections in adult patients with disease that is refractory to or who are intolerant of certain commonly used antifungal agents
The poster presentation entitled, AN2690, A Topical Antifungal Agent
In Development For The Treatment Of Onychomycosis Represents A New Class of Inhibitor With A Novel Mechanism Of Action (Poster # 769), details how Anacor scientists mapped AN2690-resistant mutations to the CDC60 gene, which codes for leucyl-tRNA synthetase, and found that the drug inhibits the editing domain of this enzyme, ultimately resulting in the interruption of protein synthesis.
Fluconazole is the generic equivalent of Pfizer's antifungal agent
Miconazole is an antifungal agent
effective against all types of oropharyngeal candidiasis with similar antimicrobial activity to ketonazole.
announced today the availability of their antifungal agent
MYCAMINE(R) (micafungin sodium) for injection in a 100mg vial format.
About CRESEMBA CRESEMBA (isavuconazonium sulfate) is the prodrug containing the active antifungal agent
isavuconazole, an azole antifungal indicated for use in the treatment of invasive aspergillosis and invasive mucormycosis.
As reported in Nature Communications, their new material proved particularly effective in destroying drug-resistant fungi and fungal biofilm, displaying great potential as an antifungal agent
to prevent and treat topical fungus-induced diseases such as skin infections and keratitis.
Propionic acid is a powerful and volatile antifungal agent
used for protecting dry agricultural products, such as grain and cereals.